RLMD
MaterialsRelmada Therapeutics Inc
Live · NASDAQ · May 9, Close
What's Moving RLMD Today?
No stock-specific AI insight has been generated for RLMD yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Trading
RLMD News
20 articles- Relmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026Yahoo Finance·May 6, 2026
- Relmada Therapeutics to Present NDV-01 Abstracts at AUA2026Yahoo Finance·May 5, 2026
- Does Relmada Therapeutics (RLMD) Have the Potential to Rally 75.58% as Wall Street Analysts Expect?Yahoo Finance·Apr 13, 2026
- Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo TherapeuticsYahoo Finance·Apr 6, 2026
- 5 Small Drug Stocks to Buy as Sector Recovery Gains StrengthYahoo Finance·Apr 2, 2026
- Wall Street Analysts Predict a 92.19% Upside in Relmada Therapeutics (RLMD): Here's What You Should KnowYahoo Finance·Mar 26, 2026
- Here’s What Makes Mizuho Bullish on Relmada Therapeutics Inc (RLMD) StockYahoo Finance·Mar 25, 2026
- Relmada Therapeutics Inc (RLMD) Q4 2025 Earnings Call Highlights: Strategic Advancements and ...Yahoo Finance·Mar 20, 2026
- Relmada Therapeutics, Inc. Q4 2025 Earnings Call SummaryMoby·Mar 20, 2026
- Relmada (RLMD) Q4 2025 Earnings Call TranscriptMotley Fool·Mar 19, 2026
- Relmada Therapeutics Q4 Earnings Call HighlightsMarketbeat·Mar 19, 2026
- Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business UpdateYahoo Finance·Mar 19, 2026
- Why Relmada Therapeutics (RLMD) Is Up 38.8% After $160M Raise And Positive NDV-01 Phase 2 DataYahoo Finance·Mar 13, 2026
- Relmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026Yahoo Finance·Mar 12, 2026
- BioGene Therapeutics Inc. Appoints Raj S. Pruthi, MD, MHA, FACS, as DirectorYahoo Finance·Mar 12, 2026
- A Look At Relmada Therapeutics (RLMD) Valuation After NDV-01 Phase 2 Update And US$160 Million Private PlacementYahoo Finance·Mar 10, 2026
- 50% and 61% Gains in a Single Day: Why XENE and RLMD Soared Today247 Wall St·Mar 9, 2026
- Relmada Therapeutics to Present at the Leerink Partners Global Healthcare ConferenceYahoo Finance·Mar 9, 2026
- Top Midday GainersYahoo Finance·Mar 9, 2026
- Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement FinancingYahoo Finance·Mar 9, 2026
All 20 articles loaded
Price Data
Fundamentals
Trading
About Relmada Therapeutics Inc
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.